文献速递生殖医学

非重型地中海贫血谱系与非地中海贫血患者体外受精及冻融胚胎移植周期的结局比较:一项倾向性评分匹配队列研究

Comparative outcomes of in vitro fertilization and frozen embryo transfer cycles in patients with nonmajor thalassemia spectrum and nonthalassemia: a propensity score-matched cohort study.
PubMed 文献 · Fertil Steril · 2025-09-09

该倾向性评分匹配回顾性队列研究纳入2013年1月至2022年12月期间41,804例接受体外受精(IVF,18,215周期)或冻融胚胎移植(FET,23,589周期)的患者,按1:2匹配非地中海贫血(NT)组(IVF n=5,816,FET n=8,004)与非重型地中海贫血谱系(NMTS)组(IVF n=2,908,FET n=4,002)。结果显示两组在卵母细胞获取率、胚胎发育(包括囊胚形成率)及妊娠结局(临床妊娠率、活产率、流产率)方面均无显著差异。

要点

  • 匹配后NT与NMTS组基线特征(包括年龄和体重指数)均衡可比。
  • IVF周期中两组临床妊娠率、活产率及流产率均相似,无显著差异。
  • FET周期中两组临床妊娠率、活产率及流产率亦相当,无显著差异。

核心结论

  • 在接受IVF或FET周期的患者中,NMTS组与NT组在胚胎发育或妊娠结局方面均未见显著差异。
  • 这些发现提示NMTS患者在辅助生殖技术中并未面临额外的生殖挑战。

研究设计与样本

  • 倾向性评分匹配回顾性队列研究。
  • 共纳入41,804例患者,其中IVF 18,215周期,FET 23,589周期,时间范围为2013年1月至2022年12月。
  • 匹配后NT组IVF n=5,816、FET n=8,004;NMTS组IVF n=2,908、FET n=4,002,匹配比例为1:2。
  • NMTS组中地中海贫血携带者占IVF病例的80.7%、FET病例的74.9%,非输血依赖型地中海贫血患者分别占19.3%和25.1%。
  • 所有患者均采用标准卵巢刺激方案(促性腺激素释放激素激动剂、促性腺激素释放激素拮抗剂及微刺激)。

主要发现

  • 匹配后NT与NMTS组基线特征(包括年龄和体重指数)可比。
  • 卵母细胞获取及胚胎发育(包括囊胚形成率)无显著差异(NT:0.54 vs NMTS:0.56)。
  • IVF周期中,临床妊娠率(aRR=1.03,95%CI 0.96-1.09)、活产率(aRR=1.02,95%CI 0.95-1.09)及流产率(aRR=1.07,95%CI 0.92-1.25)相似。
  • FET周期中,临床妊娠率(aRR=1.01,95%CI 0.96-1.07)、活产率(aRR=1.03,95%CI 0.97-1.10)及流产率(aRR=0.92,95%CI 0.81-1.04)相当。
  • 交互分析显示基线激素水平和卵巢刺激方案显著影响胚胎发育,但未影响妊娠结局。

临床怎么用

  • 作者认为这些发现可能有助于减轻NMTS患者的生殖焦虑,并在资源有限和高患病地区具有公共卫生意义,可支持临床决策并促进公平的辅助生殖技术实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether oocyte yield, embryo development, and pregnancy rates differ between patients with nonmajor thalassemia spectrum (NMTS) and nonthalassemia (NT) undergoing in vitro fertilization (IVF) or frozen embryo transfer (FET) cycles. DESIGN: A propensity score-matched retrospective cohort study. SUBJECTS: A total of 41,804 patients who underwent IVF (18,215 cycles) or FET (23,589 cycles) between January 2013 and December 2022 were included in the study. Patients were matched 1:2 for the NT (n = 5,816 IVF, n = 8,004 FET) and NMTS (n = 2,908 IVF, n = 4,002 FET) groups. Within the NMTS group, thalassemia carriers accounted for 80.7% of IVF cases and 74.9% of FET cases, whereas patients with nontransfusion-dependent thalassemia represented 19.3% and 25.1%, respectively. EXPOSURE: Standard ovarian stimulation protocols (gonadotropin-releasing hormone agonist, gonadotropin-releasing hormone antagonist, and minimal stimulation) were used for all patients. Clinical outcomes, including embryo development, clinical pregnancy, live birth, and miscarriage rates, were compared between the groups. MAIN OUTCOME MEASURES: The IVF cycle outcome (e.g., oocyte retrieval rate, fertilization rate, and blastocyst formation rate) and pregnancy outcomes (e.g., clinical pregnancy rate, live birth rate, and miscarriage rate). RESULTS: After matching, the baseline characteristics, including age and body mass index, were comparable between the NT and NMTS groups. No significant differences were observed in oocyte yield and embryo development, including blastocyst formation (NT: 0.54 vs. NMTS: 0.56). In IVF cycles, the clinical pregnancy rate (adjusted relative risk [aRR] = 1.03, 95% confidence interval [CI] = 0.96-1.09), live birth rate (aRR = 1.02, 95% CI = 0.95-1.09), and miscarriage rate (aRR = 1.07, 95% CI = 0.92-1.25) were similar. In FET cycles, the clinical pregnancy rate (aRR = 1.01, 95% CI = 0.96-1.07), live birth rate (aRR = 1.03, 95% CI = 0.97-1.10), and miscarriage rate (aRR = 0.92, 95% CI = 0.81-1.04) were comparable. Interaction analysis showed that baseline hormonal levels and ovarian stimulation protocols significantly influenced embryo development but did not affect pregnancy outcomes. CONCLUSION: No significant differences in embryo development or pregnancy outcomes were found between patients with NMTS and NT undergoing IVF or FET cycles. These findings suggest that patients with NMTS do not face additional reproductive challenges in assisted reproductive technology. This study may help reduce reproductive anxiety in patients with NMTS and has important public health relevance in resource-limited and high-prevalence regions, where it can support clinical decisions and inform equitable assisted reproductive technology care delivery.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Huang W, Wei X, Wei L, et al. Comparative outcomes of in vitro fertilization and frozen embryo transfer cycles in patients with nonmajor thalassemia spectrum and nonthalassemia: a propensity score-matched cohort study. Fertil Steril. 2025. PMID: 40935279. doi:10.1016/j.fertnstert.2025.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。